Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 131

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 131
---
 regulations of multiple jurisdictions, which may be conflicting or subject to increasing stringency or other changes, including privacy and data protection regulations, tax laws, employment laws, healthcare regulatory requirements, and other related approvals, including permitting and licensing requirements; •logistics associated with the shipment of blood, saliva, stool or tissue samples, including infrastructure conditions, transportation delays, and the impact of local laws and regulations, such as export and import restrictions, tariffs, or other charges and other trade barriers, all of which involve increased risk related to the trade policies of a jurisdiction’s current administration, which may threaten existing and proposed trade agreements and impose more restrictive export -importregulations that impact our business; •limits on our ability to penetrate international markets, including legal and regulatory requirements that would force us to conduct our tests locally by building additional laboratories or engaging in joint ventures or other relationships in order to offer our tests in certain countries, which relationships could involve significant time and resources to establish, deny us control over certain aspects of the foreign operations, or reduce the economic value to us of these operations; •failure by us, any joint venturers, or other arrangements we have or may establish, or by any distributors or other commercial partners we have engaged or may engage to obtain any regulatory approvals required to market, sell, and use our tests in various countries; 41 •challenges predicting the market for our tests and services generally and tailoring our services to meet varying customer expectations in different countries and jurisdictions; •difficulties gaining market share in jurisdictions in which we do not have a strong physical presence or brand awareness; •complexities and difficulties obtaining protection for and enforcing our intellectual property rights; •difficulties in staffing and managing foreign operations and the increased travel, infrastructure and legal compliance costs associated with multiple international locations and subsidiaries; •complexities associated with managing multiple payor coverage and reimbursement regimes, government payors, or patient self -paysystems; •financial risks, such as longer payment cycles, difficulty collecting trade accounts receivable and the impact of local and regional financial conditions on demand and payment for our tests; •exposure to foreign currency exchange rate fluctuations, conversions of currencies, and the risk of repatriation of certain foreign currencies; •natural disasters, political and economic instability, including wars (e.g., the war in Ukraine), terrorism and political unrest, outbreak of disease, boycotts, and other business restrictions; and •regulatory and compliance risks related to applicable anti -briberylaws, including requirements to maintain accurate information and control